M-1231

N/A

Report date: 2024/02/05 14:07:48

Base Information

Drug NameM-1231
Drug Alias NameM-1231
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsAnti-MUC1
TargetsEpidermal growth factor receptor erbB1Mucin-1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungEsophageal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEmd Serono Research & Development Institute IncMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesEmd Serono Research & Development Institute IncMerck KGaA, Darmstadt, Germany
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungEsophageal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A